Geburtshilfe Frauenheilkd 2020; 80(10): e195
DOI: 10.1055/s-0040-1718152
Poster
Mittwoch, 7.10.2020
Gynäkologische Onkologie II

Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study

M Klar
1   Frauenklinik des Universitätsklinikums Freiburg, Gynäkologie und Gynäkologische Onkologie, Freiburg, Deutschland
,
H Machida
2   Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan
,
B.H Grubbs
3   Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of Southern California, Los Angeles, Vereinigte Staaten von Amerika
,
S Matsuzaki
4   Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Southern California, Los Angeles, Vereinigte Staaten von Amerika
,
L.D Roman
4   Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Southern California, Los Angeles, Vereinigte Staaten von Amerika
,
A.K Sood
5   Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Vereinigte Staaten von Amerika
,
D.M Gershenson
5   Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Vereinigte Staaten von Amerika
,
K Matsuo
4   Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Southern California, Los Angeles, Vereinigte Staaten von Amerika
› Author Affiliations
› Further Information
Also available at
 

Objective To determine changes in the characteristics of low-grade serous ovarian cancer (LGSOC) and serous borderline ovarian tumor (serous-BOT) in a time-specific manner.

Methods We conducted a population-based study examining the Surveillance, Epidemiology, and End Results Program from 1988 to 2000. Trends, demographics, and outcomes of 775 women with well-differentiated serous ovarian cancer, used as a surrogate for LGSOC, were compared to 3937 women with serous-BOT.

Results In the multivariable analysis, women with LGSOC were more likely to be older, have stage II-IV disease, and have undergone hysterectomy at surgery compared to those with serous-BOT (all, adjusted-P <  0.05). During the study period, the number of LGSOCs decreased by 25.9 %, particularly stage I disease (37.6 % relative decrease) compared to stage II-IV disease (21.1 % relative decrease) (all, P <  0.05). With a median follow-up of 16.9  years, there was a decreasing trend in the 15-year overall survival rates among LGSOC (28.7 % relative decrease, P = 0.056) but not in serous-BOT (2.5 % relative increase, P = 0.416) as a whole cohort. The magnitude of hazard risk from all-cause death for women with LGSOC compared to those with serous-BOT increased by 68.9 % from 1988 to 2000 (P <  0.001). LGSOC remained an independent prognostic factor for decreased overall survival compared to serous-BOT (adjusted-P <  0.05).

Conclusion Our study suggests that the decreasing number and survival of LGSOC over time may be due to a diagnosis-shift from LGSOC to serous-BOT. Given the distinct characteristics and outcomes of LGSOC compared to serous-BOT, our study endorses the importance of making the correct diagnosis upfront.



Publication History

Article published online:
07 October 2020

© 2020. Thieme. All rights reserved.
Rüdigerstraße 14, 70469 Stuttgart, Germany